- Home
- TIL vs INMB Comparison
TIL vs INMB Comparison
Compare TIL & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- INMB
- Stock Information
- Founded
- TIL 2018
- INMB 2015
- Country
- TIL United States
- INMB United States
- Employees
- TIL N/A
- INMB N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- TIL Health Care
- INMB Health Care
- Exchange
- TIL Nasdaq
- INMB Nasdaq
- Market Cap
- TIL 171.7M
- INMB 176.5M
- IPO Year
- TIL 2021
- INMB 2019
- Fundamental
- Price
- TIL $14.48
- INMB $7.76
- Analyst Decision
- TIL Buy
- INMB Strong Buy
- Analyst Count
- TIL 5
- INMB 3
- Target Price
- TIL $114.00
- INMB $24.33
- AVG Volume (30 Days)
- TIL 178.2K
- INMB 253.3K
- Earning Date
- TIL 05-13-2025
- INMB 05-12-2025
- Dividend Yield
- TIL N/A
- INMB N/A
- EPS Growth
- TIL N/A
- INMB N/A
- EPS
- TIL N/A
- INMB N/A
- Revenue
- TIL N/A
- INMB $14,000.00
- Revenue This Year
- TIL N/A
- INMB N/A
- Revenue Next Year
- TIL N/A
- INMB N/A
- P/E Ratio
- TIL N/A
- INMB N/A
- Revenue Growth
- TIL N/A
- INMB N/A
- 52 Week Low
- TIL $9.62
- INMB $4.32
- 52 Week High
- TIL $92.00
- INMB $11.76
- Technical
- Relative Strength Index (RSI)
- TIL 46.45
- INMB 50.51
- Support Level
- TIL $10.80
- INMB $7.53
- Resistance Level
- TIL $13.52
- INMB $8.10
- Average True Range (ATR)
- TIL 2.23
- INMB 0.45
- MACD
- TIL -0.17
- INMB 0.04
- Stochastic Oscillator
- TIL 27.06
- INMB 46.15
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.